The Impact of COVID-19 is included in Glucagon-Like Peptide 1 Agonists Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Glucagon-Like Peptide 1 Agonists Trends and Forecast
The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Glucagon-Like Peptide 1 Agonists by Segment
The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.
Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:
• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide
Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:
• Byetta
• Bydureon
• Victoza
• Trulicity
• Lyxumia
Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:
• Oral
• Parenteral
• Others
Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals
• Specialty Clinics
• Others
Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Glucagon-Like Peptide 1 Agonists Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-
• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan
Glucagon-Like Peptide 1 Agonists Market Insights
Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.
North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.
Features of the Global Glucagon-Like Peptide 1 Agonists Market
Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).
Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the glucagon-like peptide 1 agonists market size?
Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.
Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?
Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?
Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.
Q4. What are the major segments for glucagon-like peptide 1 agonists market?
Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.
Q5. Who are the key glucagon-like peptide 1 agonists market companies?
Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows:
• F. Hoffmann-La Roche
• Bristol-Myers Squibb Company
• Astrazeneca
• Pfizer
• Baxter
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceuticals
• Mylan
Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?
Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.
Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.
Q8. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Glucagon-Like Peptide 1 Agonists Market, Glucagon-Like Peptide 1 Agonists Market Size, Glucagon-Like Peptide 1 Agonists Market Growth, Glucagon-Like Peptide 1 Agonists Market Analysis, Glucagon-Like Peptide 1 Agonists Market Report, Glucagon-Like Peptide 1 Agonists Market Share, Glucagon-Like Peptide 1 Agonists Market Trends, Glucagon-Like Peptide 1 Agonists Market Forecast, Glucagon-Like Peptide 1 Agonists Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Glucagon-Like Peptide 1 Agonists Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Glucagon-Like Peptide 1 Agonists Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
3.3.1: Exenatide
3.3.2: Liraglutide
3.3.3: Lixisenatide
3.3.4: Dulaglutide
3.4: Global Glucagon-Like Peptide 1 Agonists Market by Brand
3.4.1: Byetta
3.4.2: Bydureon
3.4.3: Victoza
3.4.4: Trulicity
3.4.5: Lyxumia
3.5: Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
3.5.1: Oral
3.5.2: Parenteral
3.5.3: Others
3.6: Global Glucagon-Like Peptide 1 Agonists Market by End Use
3.6.1: Hospitals
3.6.2: Specialty Clinics
3.6.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Glucagon-Like Peptide 1 Agonists Market by Region
4.2: North American Glucagon-Like Peptide 1 Agonists Market
4.2.2: North American Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
4.3: European Glucagon-Like Peptide 1 Agonists Market
4.3.1: European Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
4.3.2: European Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
4.4: APAC Glucagon-Like Peptide 1 Agonists Market
4.4.1: APAC Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
4.4.2: APAC Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
4.5: ROW Glucagon-Like Peptide 1 Agonists Market
4.5.1: ROW Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
4.5.2: ROW Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
6.1.2: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Brand
6.1.3: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
6.1.4: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by End Use
6.1.5: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Region
6.2: Emerging Trends in the Global Glucagon-Like Peptide 1 Agonists Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Glucagon-Like Peptide 1 Agonists Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glucagon-Like Peptide 1 Agonists Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: F. Hoffmann-La Roche
7.2: Bristol-Myers Squibb Company
7.3: AstraZeneca
7.4: Pfizer
7.5: Baxter
7.6: Hikma Pharmaceuticals
7.7: Amneal Pharmaceuticals
7.8: Teva Pharmaceuticals
7.9: Sun Pharmaceuticals
7.10: Mylan
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Glucagon-Like Peptide 1 Agonists Market Report.